Dr George Simon gives his thoughts on the latest key studies in locally and advanced immunotherapy developments and new agents in lung cancer, from ASCO Direct Highlights 2022.
He discusses the results of the FDA analysis which found using chemotherapy plus immunotherapy was numerically superior versus immunotherapy alone in small cell lung cancers for most patients.
Dr Simon then discusses the analysis of the S1800 data from the subset study of lung map where progression free survival was superior for pembrolizumab plus bevacizumab versus standard of care.
Further abstracts in small cell lung cancer are discussed including Skyscraper 2 and another study which found twice a day radiation therapy, compared to once a day, improved the long term quality of life for patients.
Dr Simon concludes by discussing new agents, such as the IL27 inhibitor.